Intraperitoneal therapy of ovarian cancer using an engineered measles virus

Kah Whye Peng, Cynthia J. TenEyck, Evanthia Galanis, Kimberly R. Kalli, Lynn C. Hartmann, Stephen J. Russell

Research output: Contribution to journalArticle

197 Scopus citations

Abstract

The use of replicating viruses for cancer therapy (virotherapy) holds much promise. We reported previously that the live attenuated Edmonston B vaccine strain of measles virus (MV-Edm) had antineoplastic efficacy against hematological malignancies. In this study, we demonstrate that a recombinant MV-Edm, genetically engineered to express an inert soluble marker peptide (MV-hCEA), is potent against human epithelial ovarian cancer cells in vitro and in vivo. The virus was selectively oncolytic for ovarian tumor cells but caused minimal cytopathic damage on non-transformed ovarian surface epithelium and mesothelium. In contrast to nontransformed cells, the ovarian tumor cells expressed high levels of the measles virus receptor CD46. When injected directly into large established s.c. SKOV3ip.1 human epithelial ovarian xenografts in athymic mice, the virus induced complete regression of 80% of the tumors. i.p. administration of virus enhanced the median survival of mice with advanced i.p. SKOV3ip.1 tumors by >50 days. In addition, we could easily follow the kinetic profile of viral gene expression in the treated mice by determining serum levels of the virally encoded marker peptide (soluble human carcinoembryonic antigen). Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)4656-4662
Number of pages7
JournalCancer research
Volume62
Issue number16
StatePublished - Aug 15 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intraperitoneal therapy of ovarian cancer using an engineered measles virus'. Together they form a unique fingerprint.

  • Cite this